Triggered by the achievement of $3B in global Darzalex (daratumumab) sales in 2019, Genmab A/S (NASDAQ:GMAB) earns a $150M milestone payment from Johnson & Johnson (NYSE:JNJ) unit Janssen Biotech.
It also earns royalties on net sales under the exclusive license agreement.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.